

SANTE DATA COLLECTION PLATFORM

Eradication: Final report for Lumpy Skin Disease 2018

For each approved annual or multi-annual programme Member States shall submit to the Commission by the 30 April each year an annual detailed technical and financial report covering the previous year. That report shall include the results achieved and a detailed account of eligible costs incurred (Art 14 of Regulation (EU) No 652/2014).

This form is for information only, no submission possible.

ID: 20190720-T5GKRY5U

Country code: BG

Reporting period

1. Technical implementation of the programme

1.1 Description and evaluation of the evolution of the epidemiological situation, the technical implementation of the activities foreseen under the programme and the cost-effectiveness of the programme.

With regard to the control of LSD, Bulgaria implemented a vaccination programme against LSD of the entire bovine population , as per the provisions of CID 2016/2009 and CID 2016/2008. Clinical examinations were carried out within the implementation of other control Programmes (TADs Programme, BT control programme). Laboratory surveillance is carried out in case of suspicion. No positive outbreaks has been recorded in Bulgaria since 1st August 2016 as by now. The LSD control programme includes vaccination against LSD on entire bovine population since 2016, as per the vacination programme approved by CID 2009/2016

1.2 Details on the level of achievement of the targets set in the approved programme and technical difficulties.

Clinical examinations for LSD in the six bordering regions in the South part of the country as follows: Burgas, Yambol, Haskovo, Kardzhali, Smolyan, Blagoevgrad were performed.

No clinical signs suggesting LSD were detected during the period.

No clinical signs or any suspicion were raised for LSD within the reporting period.

For the purpose of vaccination, Bulgaria supplied vaccine doses as follows:

- 261 475 doses leftover from the vaccination carried out in 2017 (supplied from Huvepharma by the BFSA). These doses are presented in the reimbursement claim

20190720-T5GKRY5U Page 1/3

- 249 200 "Lumpyvax" donation by Austria (in total of 249 200 doses)(Please see the Annex II on the Programme of the Lumpy skin disease (LSD) vaccination programme, carried out with LSD vaccine doses donated by Austria in Febr 2018)
- 249 600 "Lumpyvax" second donation by Austria in June 2018
- 30 450 doses left for 2019

729 825 vaccine doses used within the reporting period

Within the reporting period 835000 vaccine doses Boviax LSD N were purchased to be used for vaccination in 2019. The cost incurred are included in the present Financial report.

1.3 Epidemiological maps for infection and other relevant data on the disease/activities (information on serotypes involved,...) (Please attach files of data using the PDF attachement feature) Use the textbox below to provide clarifications for the maps you attach, if needed.

N/A

2. TECHNICAL IMPLEMENTATION ON RUMINANT DISEASES PROGRAMMES

VERY IMPORTANT: Please fill out the following tables with figures corresponding to measures performed during the implementing period (1/1 to 31/12).

Table A - DATA ON HERDS

Region	Animal species	Total number of herds	Total number of herds under the programme	Number of herds to be checked under the programme this year	Number of herds checked	Number of positive herds	Number of new positive herds	Number of herds depo- pulated
		% of herds depopulated	s depopulated % of herds coverage % of positive he Period herd prev			% of positive herds Herd incidence		
The whole territory of the country	Cattle	56,100	56,100	56,100	56,100	0	0	0
		%		100 %		0 %		0 %
Total		56,100	56,100	56,100	56,100	0	0	0
		%		100 %		0 %		0 %

Table B - DATA ON ANIMALS

Region	Animal species	Total number of animals	Number of animals under the programme	Number of animals to be tested under the programme this year	Number of animals tested	Number of animals tested individually	Number of positive animals	Number of animals with positive result slaugh- tered or culled	Number of animals slaugh- tered
		% coverage a	at animals lev	el		% positive animals Animal Prevalence			
All	Cattle	773,050	680,042	0	0	0	0	0	0
			%					%	
Total		773,050	680,042	0	0	0	0	0	0
		%						%	

Table C - DATA ON VACCINATION PROGRAMMES

Region	Animal species	Total number of herds	Total number of animals	Number of herds in vaccination programme this year	Number of herds vaccinated	Number of animals vaccinated	Number of doses of vaccine admini- stered	Number of adults vaccinated	Number of young animals vaccinated	Number of animals with primary vaccination (initial+ booster)
All	Cattle	56,100	773,050	680,042	56,100	680,042	729,825	0	0	0
Total		56,100	773,050	680,042	56,100	680,042	729,825	0	0	0

Table D - DATA ON STATUS OF HERDS AT THE END OF THE PERIOD

Region	Animal species	Total number of herds and animals under the programme	Unknown		Not free or not officially free from disease		Free from disease	Officially free from disease
		p. cg		Last check positive	Last check negative	withdrawn		

20190720-T5GKRY5U Page 2/3

Total - herds	0	0	0	0	0	0	0
Total - animals	0	0	0	0	0	0	0

Table E - SUSPENSION/WITHDRAWAL OF THE FREE OR OFFICIALLY FREE STATUS

Region	Animal species	Status	Reason	Number of herds
Total				0

Table F - STRATIFIED DATA ON SURVEILLANCE AND LABORATORY TESTS

Region	Animal species	Test type	Number of samples	Number of tests	Number of positive tests
Total			0	0	0
			Methods of laboratory analysis	Total number of tests	

COMMENT / ADDITIONAL CLARIFICATION

The total vaccine doses used for the implementation of the vaccination programme: 729 825

- 261 475 doses were purchased by the country itself and are presented in the reimbursement claim
- 468 350 "Lumpyvax" doses donated by Austria were used (out of 498 800 in total)

In total 56100 bovine herds, 773050 bovines were subject of the LSD control programme. Number of vaccinated animals in 680042.

Within the reporting period, 835 000 vaccine doses Boviax LSD N were purchased to be used for vaccination in 2019. The cost incurred is in total 2,429,300.00 without VAT (2,915,160.00 with VAT).

1.8.9 SANTE Data Collection Platform - PRODUCTION • Contact us at SANTE-XMLGATE3@ec.europa.eu

20190720-T5GKRY5U Page 3/3